Circulating MicroRNAs in Small-bowel Neuroendocrine Tumors: A Potential Tool for Diagnosis and Assessment of Effectiveness of Surgical Resection
- PMID: 31373926
- DOI: 10.1097/SLA.0000000000003502
Circulating MicroRNAs in Small-bowel Neuroendocrine Tumors: A Potential Tool for Diagnosis and Assessment of Effectiveness of Surgical Resection
Abstract
Objective: To discover serum-based microRNA (miRNA) biomarkers for small-bowel neuroendocrine tumors (SBNET) to help guide clinical decisions.
Background: MiRNAs are small noncoding RNA molecules implicated in the initiation and progression of many cancers. MiRNAs are remarkably stable in bodily fluids, and can potentially be translated into clinically useful biomarkers. Novel biomarkers are needed in SBNET to determine disease aggressiveness, select patients for treatment, detect early recurrence, and monitor response.
Methods: This study was performed in 3 stages (discovery, validation, and a prospective, longitudinal assessment). Discovery comprised of global profiling of 376 miRNA in sera from SBNET patients (n = 11) versus healthy controls (HCs; n = 3). Up-regulated miRNAs were subsequently validated in additional SBNET (n = 33) and HC sera (n = 14); and then longitudinally after SBNET resection (n = 12), with serial serum sampling (preoperatively day 0; postoperatively at 1 week, 1 month, and 12 months).
Results: Four serum miRNAs (miR-125b-5p, -362-5p, -425-5p and -500a-5p) were significantly up-regulated in SBNET (P < 0.05; fold-change >2) based on multiple normalization strategies, and were validated by RT-qPCR. This combination was able to differentiate SBNET from HC with an area under the curve of 0.951. Longitudinal assessment revealed that miR-125b-5p returned towards HC levels at 1 month postoperatively in patients without disease, whereas remaining up-regulated in those with residual disease (RSD). This was also true at 12 months postoperatively. In addition, miR-362-5p appeared up-regulated at 12 months in RSD and recurrent disease (RCD).
Conclusions: Our study represents the largest global profiling of serum miRNAs in SBNET patients, and the first to evaluate ongoing serum miRNA expression changes after surgical resection. Serum miR-125b-5p and miR-362-5p have potential to be used to detect RSD/RCD.
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
The authors report no conflicts of interest.
Similar articles
-
MicroRNAs associated with small bowel neuroendocrine tumours and their metastases.Endocr Relat Cancer. 2016 Sep;23(9):711-26. doi: 10.1530/ERC-16-0044. Epub 2016 Jun 27. Endocr Relat Cancer. 2016. PMID: 27353039
-
Overexpression of MicroRNA miR-7-5p Is a Potential Biomarker in Neuroendocrine Neoplasms of the Small Intestine.Neuroendocrinology. 2018;106(4):312-317. doi: 10.1159/000480121. Epub 2017 Aug 19. Neuroendocrinology. 2018. PMID: 28848144
-
Identification of a four-microRNA panel in serum for screening renal cell carcinoma.Pathol Res Pract. 2021 Nov;227:153625. doi: 10.1016/j.prp.2021.153625. Epub 2021 Sep 24. Pathol Res Pract. 2021. PMID: 34628264
-
Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non-small cell lung cancer patients.Curr Probl Cancer. 2020 Aug;44(4):100540. doi: 10.1016/j.currproblcancer.2020.100540. Epub 2020 Jan 23. Curr Probl Cancer. 2020. PMID: 32007320 Review.
-
A Comprehensive Assessment of the Role of miRNAs as Biomarkers in Gastroenteropancreatic Neuroendocrine Tumors.Neuroendocrinology. 2018;107(1):73-90. doi: 10.1159/000487326. Epub 2018 Mar 22. Neuroendocrinology. 2018. PMID: 29566385 Review.
Cited by
-
Micro-RNA 122 and micro-RNA 96 affected human osteosarcoma biological behavior and associated with prognosis of patients with osteosarcoma.Biosci Rep. 2020 Dec 23;40(12):BSR20201529. doi: 10.1042/BSR20201529. Biosci Rep. 2020. PMID: 33078195 Free PMC article.
-
Management of Small Bowel Neuroendocrine Tumours: 10 Years' Experience at a Tertiary Referral Centre.Cancers (Basel). 2023 Sep 6;15(18):4438. doi: 10.3390/cancers15184438. Cancers (Basel). 2023. PMID: 37760408 Free PMC article.
-
Drug Discovery and Development of miRNA-Based Nucleotide Drugs for Gastrointestinal Cancer.Biomedicines. 2023 Aug 9;11(8):2235. doi: 10.3390/biomedicines11082235. Biomedicines. 2023. PMID: 37626731 Free PMC article. Review.
-
The uprise of RNA biology in neuroendocrine neoplasms: altered splicing and RNA species unveil translational opportunities.Rev Endocr Metab Disord. 2023 Apr;24(2):267-282. doi: 10.1007/s11154-022-09771-4. Epub 2022 Nov 24. Rev Endocr Metab Disord. 2023. PMID: 36418657 Free PMC article. Review.
-
Neuroendocrine Neoplasms of the Small Bowel and Pancreas.Neuroendocrinology. 2020;110(6):444-476. doi: 10.1159/000503721. Epub 2019 Sep 27. Neuroendocrinology. 2020. PMID: 31557758 Free PMC article. Review.
References
-
- Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017; 3:1335–1342.
-
- Arvidsson Y, Rehammar A, Bergstrom A, et al. miRNA profiling of small intestinal neuroendocrine tumors defines novel molecular subtypes and identifies miR-375 as a biomarker of patient survival. Mod Pathol 2018; 31:1302–1317.
-
- Frilling A, Modlin IM, Kidd M, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 2014; 15:e8–e21.
-
- Mabert K, Cojoc M, Peitzsch C, et al. Cancer biomarker discovery: current status and future perspectives. Int J Radiat Biol 2014; 90:659–677.
-
- Norlen O, Stalberg P, Oberg K, et al. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg 2012; 36:1419–1431.